2024
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
Taylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024 PMID: 39183466, DOI: 10.1111/bju.16509.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing therapyUpfront RCRadical cystectomyCohort of patientsBladder cancerBCG-unresponsive NMIBCRetrospective cohort of patientsProgression to MIBCUpfront radical cystectomyCancer-specific survivalInstitutional review board approvalMetastasis-free survivalFood and Drug Administration criteriaRate of recurrenceReview board approvalLong-term outcomesStatistically significant differenceNodal diseaseRe-resectionSystemic immunotherapyIntravesical chemotherapyOncological outcomesOverall survivalOncological riskBladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024 PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer expertsChallenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? European Urology 2024, 86: 366-368. PMID: 38879371, DOI: 10.1016/j.eururo.2024.05.027.Peer-Reviewed Original ResearchMale Robot-Assisted Radical Cystectomy with Nerve Sparing Technique
Tan W, Ta A, Sridhar A, Kelly J. Male Robot-Assisted Radical Cystectomy with Nerve Sparing Technique. 2024, 291-302. DOI: 10.1007/978-3-031-49428-4_23.Peer-Reviewed Original ResearchHematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria
Tan W, Ahmad A, Zhou Y, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Smith R, Khalifeh M, Tan W, Cohen D, Volanis D, Walter F, Sasieni P, Kamat A, Kelly J. Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. European Urology Oncology 2024 PMID: 38811250, DOI: 10.1016/j.euo.2024.05.005.Peer-Reviewed Original ResearchCancer risk scoreRenal bladder ultrasoundTa bladder cancerUrinary tract cancerRisk scoreValidation cohortBladder cancerHealth care cost savingsBladder ultrasoundDiagnosis of urinary tract cancerInvasive proceduresDevelopment cohortIdentification of cancerSuspicion of bladder cancerSecondary careIndependent validation cohortReceiver operating characteristic curveUK hospitalsArea under the receiver operating characteristic curveOutcome measuresTriage of patientsConsecutive patientsPatient cohortCystoscopyHematuriaMP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. MP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE. Journal Of Urology 2024, 211: e241. DOI: 10.1097/01.ju.0001008640.01272.9d.06.Peer-Reviewed Original ResearchMP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. MP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT? Journal Of Urology 2024, 211: e242. DOI: 10.1097/01.ju.0001008640.01272.9d.08.Peer-Reviewed Original ResearchPD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. PD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN. Journal Of Urology 2024, 211: e627. DOI: 10.1097/01.ju.0001008848.77629.6f.08.Peer-Reviewed Original ResearchMP24-20 IMPACT OF MENTAL HEALTH ILLNESS ON ADHERENCE TO SURVEILLANCE AND TREATMENT GUIDELINES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Grajales V, Duan Z, Tan W, Contieri R, Myers A, Zhao H, Giordano S, Williams S, Kamat A. MP24-20 IMPACT OF MENTAL HEALTH ILLNESS ON ADHERENCE TO SURVEILLANCE AND TREATMENT GUIDELINES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS. Journal Of Urology 2024, 211: e401. DOI: 10.1097/01.ju.0001008860.46052.c4.20.Peer-Reviewed Original ResearchMP35-06 PICTURE PERFECT DIAGNOSES: EVALUATING UROLOGISTS' TUMOR IDENTIFICATION SKILLS: THE PROSPECTIVE TUMOR GRADING VISUAL ACCURACY (TRIVIA) STUDY
Grajales V, Contieri R, Tan W, Tuke D, Akhverdiyeva L, Hwang H, Myers A, Kamat A. MP35-06 PICTURE PERFECT DIAGNOSES: EVALUATING UROLOGISTS' TUMOR IDENTIFICATION SKILLS: THE PROSPECTIVE TUMOR GRADING VISUAL ACCURACY (TRIVIA) STUDY. Journal Of Urology 2024, 211: e582. DOI: 10.1097/01.ju.0001009372.61513.54.06.Peer-Reviewed Original ResearchConservative versus liberal oxygen therapy for intensive care unit patients: meta-analysis of randomized controlled trials
Li X, Dai B, Hou H, Zhao H, Wang W, Kang J, Tan W. Conservative versus liberal oxygen therapy for intensive care unit patients: meta-analysis of randomized controlled trials. Annals Of Intensive Care 2024, 14: 68. PMID: 38668955, PMCID: PMC11052962, DOI: 10.1186/s13613-024-01300-7.Peer-Reviewed Original ResearchIntensive care unit patientsLiberal oxygen therapyConservative oxygen therapyIntensive care unitRandomized controlled trialsHospital length of stayLength of stayOxygen therapyControlled trialsClinical outcomesHospital lengthMeta-analysis of randomized controlled trialsClinical outcomes of ICU patientsIntensive care unit length of stayIntensive care unit lengthOutcomes of ICU patientsCochrane Central Register of Controlled TrialsMeta-analysisCentral Register of Controlled TrialsMethodsWe systematically searched PubMedMechanical ventilation supportRegister of Controlled TrialsOutcomes of intensive care unitCochrane Central RegisterSystematically searched PubMedONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Annapureddy D, Taylor J, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Facundo D, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars And Original Investigations 2024, 42: s52-s53. DOI: 10.1016/j.urolonc.2024.01.160.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsive NMIBCMultinational cohort of patientsUpfront RCCancer-specific survivalInvasive bladder cancerRadical cystectomyOncological outcomesCohort of patientsAdequate BCGBCG therapyBCG-unresponsiveSalvage therapySpecific survivalBladder cancerMultinational cohortBCG-unresponsive NMIBC patientsAdequate BCG therapyBladder sparing therapyCombination intravesical therapyMaintenance BCG therapyNode positivity rateCompare oncologic outcomesNATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT
Taylor J, Annapureddy D, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Davaro F, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT. Urologic Oncology Seminars And Original Investigations 2024, 42: s49. DOI: 10.1016/j.urolonc.2024.01.152.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBCG-unresponsive NMIBCBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsiveRate of cystectomyCohort of patientsOncological outcomesRadical cystectomyBladder cancer deathAdequate BCGBCG therapyOncological riskCancer deathRetrospective multi-center cohortInternational cohort of patientsAdequate BCG therapyAlternative intravesical agentsIntravesical mitomycin CMaintenance BCG therapyNatural historyUpfront radical cystectomyInferior oncologic outcomesMulti-center cohort of patientsUpper tract diseaseA0739 Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. A0739 Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect? European Urology 2024, 85: s1712-s1713. DOI: 10.1016/s0302-2838(24)01310-1.Peer-Reviewed Original ResearchA0742 The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance
Contieri R, Tan W, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. A0742 The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance. European Urology 2024, 85: s1717. DOI: 10.1016/s0302-2838(24)01313-7.Peer-Reviewed Original Research‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder
Myers A, Tan W, de Groot J, Westney O, Kamat A. ‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU International 2024, 134: 45-47. PMID: 38379218, DOI: 10.1111/bju.16302.Peer-Reviewed Original ResearchInfluence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristicsAssociation of Age with Non–muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?
Lobo N, Duan Z, Sood A, Tan W, Grajales V, Contieri R, Lindskrog S, Dyrskjøt L, Zhao H, Giordano S, Williams S, Bree K, Kamat A. Association of Age with Non–muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? European Urology Oncology 2024, 7: 1069-1079. PMID: 38302322, DOI: 10.1016/j.euo.2024.01.011.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder cancer-specific mortalitySEER-Medicare dataSEER-MedicareAge disparitiesTumor biologyAdequate cancer careEnd Results (SEER)-MedicareSEER-Medicare cohortBladder cancerUROMOL cohortOncological outcomesMultivariate general linear modelCancer-specific mortalitySEER-Medicare patientsMultinomial logistic regressionAssociation of ageAssociated with inferior oncological outcomesCompeting-risks regressionCancer careAdvanced ageT1 non-muscle-invasive bladder cancerHigh risk of recurrenceClinical stage TaMultivariable competing-risks regressionComparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis
Wang J, Peng Y, Dai B, Hou H, Zhao H, Wang W, Tan W. Comparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis. Therapeutic Advances In Respiratory Disease 2024, 18: 17534666231225323. PMID: 38230522, PMCID: PMC10798115, DOI: 10.1177/17534666231225323.Peer-Reviewed Original ResearchConceptsAcute hypoxemic respiratory failureHigh-flow nasal cannulaConventional oxygen therapyCOVID-19-related acute hypoxemic respiratory failureIntensive care unitHospital length of stayInvasive mechanical ventilationLength of stayIntensive care unit settingCOVID-19 patientsIntubation rateNasal cannulaMechanical ventilationOxygen therapyRatio of arterial oxygen partial pressure to fractional inspired oxygenHospital lengthArterial oxygen partial pressure to fractional inspired oxygenEfficacy of high-flow nasal cannulaIntensive care unit length of stayControlled trialsSystematic reviewRespiratory support strategiesIntensive care unit lengthHypoxemic respiratory failureMortality rate
2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian follow-upRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective study